HER2阳性乳腺癌靶向治疗药物Herceptin耐药机制的新进展

New progress in Herceptin resistance mechanism of HER2 positive breast cancer targeted therapy

人类表皮生长因子受体2 (human epidermal growth factor receptor 2, HER2)是乳腺癌中最重要的癌基因,在乳腺癌细胞的增殖、侵袭、转移和演化等过程中发挥着重要作用。Herceptin,一种人源化单克隆抗体,已广泛用于HER2阳性乳腺癌患者的临床治疗中,疗效显著,并已成为靶向治疗的一线药。然而,大部分HER2阳性的乳腺癌患者在接受Herceptin治疗一年后会发生耐药。现对Herceptin耐药的可能机制、恢复药物敏感性的可能方法及最新研究进展进行综述,以期为Herceptin耐药研究提供新的思路。

Human epidermal growth factor receptor 2(HER2) is the most important oncogene in breast cancer and plays an important role in the proliferation, invasion, metastasis and evolution of breast cancer cells. Herceptin, a humanized monoclonal antibody, has been widely used in the clinical treatment of HER2-positive breast cancer patients. It has a remarkable effect and has become a first-line drug for targeted therapy. However, most HER2-positive breast cancer patients develop resistance after one year of Herceptin treatment. This article will review the possible mechanisms of Herceptin resistance, the possible methods of restoring drug susceptibility and the latest research progress, and provide new ideas for Herceptin resistance research.